Mereo BioPharma Group plc

Ownership Transactions Reported by 15 Insiders

Symbol
MREO on Nasdaq
Location
One Cavendish Place, Fourth Floor, London, United Kingdom

There are no Buy or Sell transactions made by insiders since 10/7/2024

Mereo BioPharma Group plc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Rubric Capital Management LP 10%+ Owner $61.1M Jun 17, 2024
Denise Scots-Knight Chief Executive Officer $4.25M Jan 25, 2025
Charles Sermon General Counsel $1.19M Jan 25, 2025
Christine Fox Chief Financial Officer $641K Jan 25, 2025
John A. Lewicki Chief Scientific Officer $509K Jan 25, 2025
Alexandra Hughes-Wilson Chief Patient Access and Commercial Planning $369K Jan 25, 2025
Michael S. Wyzga Director $156K Feb 5, 2025
Jeremy Bender Director $106K Feb 5, 2025
Marc J. Yoskowitz Director $55.6K Feb 5, 2025
Pierre Jacquet Director $55.6K Feb 5, 2025
Annalisa Jenkins Director $55.6K Feb 5, 2025
Anders Ekblom Director $55.6K Feb 5, 2025
Daniel Shames Director $55.6K Feb 5, 2025
Deepika Pakianathan Director $55.6K Feb 5, 2025
Justin Hunter Roberts Director Jan 1, 2024

Recent Insider Transactions by Companies or Individuals for Mereo BioPharma Group plc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.